0000882291
false
0000882291
2023-06-28
2023-06-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 28, 2023
AETHLON
MEDICAL, INC.
(Exact name of Registrant as Specified in Its
Charter)
Nevada |
001-37487 |
13-3632859 |
(State or Other Jurisdiction of
Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
11555
Sorrento Valley Road, Suite
203
San Diego, California |
92121 |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s Telephone Number, Including
Area Code: (619) 941-0360
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
AEMD |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition. |
On June 28, 2023, Aethlon Medical, Inc. issued
a press release announcing its financial results for the fiscal year ended March 31, 2023. A copy of this press release is attached hereto
as Exhibit 99.1.
The information in this Item 2.02 and the exhibit
hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 28, 2023 |
Aethlon Medical, Inc. |
|
|
|
|
|
|
|
By: |
|
/s/ James B. Frakes |
|
Name:
|
|
James B. Frakes
Chief Financial Officer |
Exhibit 99.1
Aethlon Medical Announces Fiscal Year End Financial
Results and Provides Corporate Update
Conference Call to be Held Today at 4:30pm
ET
SAN DIEGO, June 28, 2023 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a
medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial
results for its fiscal year ended March 31, 2023 and provided an update on recent developments.
Company Updates
Aethlon Medical
is continuing the research and clinical development of its Hemopurifier®,
a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood. This action has
potential applications in cancer, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening
infectious diseases.
The company’s ongoing COVID-19 trial in India, for patients in
the intensive care unit (ICU) at Medanta Medicity Hospital, remains open for enrollment, with one patient treated to date. In May 2023,
a second clinical site, Maulana Azad Medical College (MAMC), received Ethics Board Approval to participate in the trial and site activation
activities are currently underway. Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of
MAMC as a second, high quality clinical site may improve the enrollment of patients who go on to require ICU care for severe infection.
In the oncology indication, Aethlon Medical continues to work with
its contract research organization, North American Science Associates, LLC (NAMSA), to initiate a clinical trial in Australia. This new
clinical trial in oncology is planned to be a safety, feasibility and dose finding trial in solid tumors failing anti-PD-1 antibodies.
Management of Aethlon Medical believes that the data from this trial will help inform the design of future efficacy trials of the company’s
Hemopurifier in oncology. Current activities include site identification and qualification, finalization of necessary documents for Ethics
Board submission, case report form development and selection of a Data Safety Monitoring Board.
On June 21,
2023, Aethlon announced that it is investigating the use of its Hemopurifier
in the organ transplant market. Specifically, the company is conducting
translational studies with the objective of determining if the Hemopurifier, when incorporated into a machine perfusion organ preservation
circuit, can remove harmful viruses and exosomes from harvested organs. The company
has previously demonstrated the removal
of multiple viruses and exosomes from buffer solutions, in vitro, utilizing a scaled-down version of the Hemopurifier. This process potentially
may reduce complications following transplantation of the harvested organ, which can include viral infection, delayed graft function and
rejection. The company believes that this new approach could be additive to existing technologies that are currently in place to increase
the number of viable organs for transplant.
According to Precedence Research, the size of the global organ transplantation
market is projected to hit approximately $33.7 billion by 2032, compared to $15.1 billion in 2022. Further, Precedence Research estimates
that the global organ transplantation market is poised to expand at a compounded average growth rate of 8.36% during the forecast period
of 2023 to 2032. Additionally, according to Precedence Research, rising demand for organ transplantation to treat organ failure and novel
tissue transplantation products is the prime factor that is driving market growth.
In the United States, all organ transplant programs must be located
in hospitals that have a Medicare provider agreement. The ultimate goal of Aethlon Medical's research in the organ transplantation area
is to position the Hemopurifier as a beneficial and potentially transformative accessory element to existing or future organ perfusion
systems that keep harvested organs in transplantable condition.
Financial Results for the Fiscal Year Ended March 31, 2023
As of March 31, 2023, Aethlon Medical had a cash balance of approximately
$14.5 million.
Consolidated operating expenses for the fiscal year ended March 31,
2023 were approximately $12.47 million, compared to $10.71 million for the fiscal year ended March 31, 2022, an increase of approximately
$1.76 million. The $1.76 million increase in the fiscal year ended March 31, 2023 was due to increases in administrative expense of $1.03
million and professional fees of approximately $910,000, which were partially offset by a decrease in payroll and related expenses of
approximately $180,000.
General and administrative expense for the fiscal year ended March
31, 2023 was $4.48 million, compared to $3.45 million for the fiscal year ended March 31, 2022. The $1.03 million increase for the fiscal
year ended March 31, 2023 was due to an increase in manufacturing and research and development supplies of approximately $400,000 related
to the manufacture of the Hemopurifier device and various research and development activities. Other increases included approximately
$147,000 in subcontract expense related to revenue recognized from contracts and grants with the NIH; approximately $155,000 associated
with the close out of the U.S. COVID-19 clinical trial; approximately $104,000 associated with the company’s Australian subsidiary
and launch of the oncology clinical trial in Australia; approximately $118,000 in rent expense related to the addition of the manufacturing
suite in fiscal year 2023 and a full year of rent for the company’s office and laboratory space; approximately $117,000 in depreciation
and amortization expense associated with leasehold improvements to manufacturing space and; approximately $94,000 in D&O and medical
insurance. The company also had an increase in utility expense of approximately $32,000, largely as the result of the increased space
under lease. These increases were offset by decreases in outside services of approximately $65,000, laboratory fees of approximately $61,000
and decreases in office supplies and equipment of approximately $32,000.
Professional fees for the fiscal year ended March 31, 2023 were $3.54
million compared to $2.63 million in the fiscal year ended March 31, 2022. The approximately $910,000 increase in the fiscal year ended
March 31, 2023 was primarily due to increases of approximately $291,000 in legal expenses, approximately $335,000 in contract labor associated
with product development and scientific analytical services, approximately $176,000 in regulatory consulting, approximately $40,000 in
investor relations, approximately $73,000 in recruiting expense and approximately $16,000 in director fees, which were partially offset
by a decrease in accounting fees of approximately $17,000.
Aethlon Medical’s National Cancer Institute (NCI) award contract
ended on September 15, 2022 and the company subsequently presented the required final report to the NCI. As the NCI completed its close
out review of the contract, Aethlon Medical recorded total government contract revenue of approximately $574,000 in the fiscal year ended
March 31, 2023 compared to approximately $294,000 in the fiscal year ended March 31, 2022.
As a result of the above factors, the company’s net loss before
noncontrolling interests increased to $12.0 million for the fiscal year ended March 31, 2023, from $10.4 million for the fiscal year ended
March 31, 2022.
During the fiscal year ended March 31, 2023, the company raised approximately
$8.9 million in net proceeds under its At The Market Offering Agreement with H.C. Wainwright & Co. (ATM agreement), pursuant to sales
of its common stock. Subsequent to March 31, 2023, the company raised net proceeds of approximately $1.1 million under the ATM agreement.
The condensed consolidated balance sheet for March 31, 2023, and the
condensed consolidated statements of operations for the fiscal years ended March 31, 2023 and 2022 follow at the end of this release.
Conference Call
Aethlon Medical will hold a conference
call today, Wednesday, June 28, 2023, at 4:30 p.m. ET to review its financial results for its fiscal year ended March 31, 2023 and recent
corporate developments. Interested parties can register for the conference at https://dpregister.com/sreg/10180154/f9c217a958.
Please note that registered participants will receive their dial in number upon registration.
Interested parties without internet access or who are unable to pre-register,
may dial in as follows:
Participant Dial In (Toll Free): 1-844-836-8741
Participant International Dial In: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after
the end of the event, through July 28, 2023. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic)
or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 9371984.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening
viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from
blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote
immune suppression and metastasis, and in life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration
(FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development
or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption
(IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate,"
"expect," "intend," "plan," "project," "will," "projections," "estimate,"
"potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant
risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove
to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to successfully complete
development of the Hemopurifier and to successfully demonstrate the utility of the Hemopurifier combatting cancer and life-threatening
viruses and in the organ transplant field, the Company’s ability to manage its clinical trials and to successfully enroll patients
in clinical trials, the Company’s ability to raise additional funds, and other potential risks. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated
in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for
the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly
Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made.
Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future
events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
| |
March 31, 2023 | | |
March 31, 2022 | |
ASSETS | |
| | |
| |
CURRENT ASSETS | |
| | | |
| | |
Cash | |
$ | 14,532,943 | | |
$ | 17,072,419 | |
Accounts receivable | |
| – | | |
| 127,965 | |
Prepaid expenses | |
| 557,623 | | |
| 956,623 | |
TOTAL CURRENT ASSETS | |
| 15,090,566 | | |
| 18,157,007 | |
| |
| | | |
| | |
Property and equipment, net | |
| 1,144,004 | | |
| 441,238 | |
Right-of-use lease asset | |
| 1,151,909 | | |
| 696,698 | |
Patents, net | |
| 1,650 | | |
| 2,200 | |
Restricted cash | |
| 87,506 | | |
| 87,506 | |
Deposits | |
| 33,305 | | |
| 33,305 | |
TOTAL ASSETS | |
$ | 17,508,940 | | |
$ | 19,417,954 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable | |
$ | 432,889 | | |
$ | 499,962 | |
Due to related parties | |
| 214,221 | | |
| 155,742 | |
Deferred revenue | |
| – | | |
| 344,547 | |
Lease liability, current portion | |
| 269,386 | | |
| 126,905 | |
Other current liabilities | |
| 588,592 | | |
| 696,893 | |
TOTAL CURRENT LIABILITIES | |
| 1,505,088 | | |
| 1,824,049 | |
| |
| | | |
| | |
Lease liability, less current portion | |
| 939,642 | | |
| 602,505 | |
TOTAL LIABILITIES | |
| 2,444,730 | | |
| 2,426,554 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Common stock, par value of $0.001, 60,000,000 shares authorized; 22,992,466 and 15,419,163 issued and
outstanding |
|
|
22,994 |
|
|
|
15,421 |
|
Additional paid in capital | |
| 157,405,911 | | |
| 147,446,868 | |
Accumulated other comprehensive loss | |
| (6,141 | ) | |
| – | |
Accumulated deficit | |
| (142,358,554 | ) | |
| (130,329,181 | ) |
TOTAL STOCKHOLDERS' EQUITY BEFORE NONCONTROLLING INTERESTS | |
| 15,064,210 | | |
| 17,133,108 | |
| |
| | | |
| | |
Noncontrolling interests | |
| – | | |
| (141,708 | ) |
| |
| | | |
| | |
TOTAL STOCKHOLDERS' EQUITY | |
| 15,064,210 | | |
| 16,991,400 | |
| |
| | | |
| | |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | |
$ | 17,508,940 | | |
$ | 19,417,954 | |
AETHLON MEDICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
For the fiscal years ended March 31, 2023 and 2022
| |
Fiscal Year | | |
Fiscal Year | |
| |
Ended 3/31/23 | | |
Ended 3/31/22 | |
| |
| | |
| |
Government contract revenue | |
$ | 574,245 | | |
$ | 294,165 | |
| |
| | | |
| | |
OPERATING COSTS AND EXPENSES | |
| | | |
| | |
| |
| | | |
| | |
Professional fees | |
| 3,548,028 | | |
| 2,634,026 | |
Payroll and related | |
| 4,443,552 | | |
| 4,625,802 | |
General and administrative | |
| 4,481,303 | | |
| 3,455,222 | |
| |
| 12,472,883 | | |
| 10,715,050 | |
OPERATING LOSS | |
| (11,898,638 | ) | |
| (10,420,885 | ) |
| |
| | | |
| | |
OTHER EXPENSE (INCOME) | |
| | | |
| | |
Loss on dissolution of subsidiary | |
| 142,121 | | |
| – | |
Interest income | |
| (10,973 | ) | |
| – | |
| |
| 131,148 | | |
| – | |
| |
| | | |
| | |
NET LOSS BEFORE NONCONTROLLING INTERESTS | |
$ | (12,029,786 | ) | |
$ | (10,420,885 | ) |
| |
| | | |
| | |
Loss attributable to noncontrolling interests | |
| – | | |
| (4,794 | ) |
| |
| | | |
| | |
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | |
$ | (12,029,786 | ) | |
$ | (10,416,091 | ) |
| |
| | | |
| | |
OTHER COMPREHENSIVE LOSS | |
| (6,141 | ) | |
| – | |
| |
| | | |
| | |
COMPREHENSIVE LOSS | |
$ | (12,035,927 | ) | |
$ | (10,416,091 | ) |
| |
| | | |
| | |
Basic and diluted net loss available to common stockholders per share | |
$ | (0.59 | ) | |
$ | (0.71 | ) |
| |
| | | |
| | |
Weighted average number of common shares outstanding | |
| 20,537,434 | | |
| 14,756,967 | |
v3.23.2
Cover
|
Jun. 28, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jun. 28, 2023
|
Entity File Number |
001-37487
|
Entity Registrant Name |
AETHLON
MEDICAL, INC.
|
Entity Central Index Key |
0000882291
|
Entity Tax Identification Number |
13-3632859
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
11555
Sorrento Valley Road
|
Entity Address, Address Line Two |
Suite
203
|
Entity Address, City or Town |
San Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92121
|
City Area Code |
619
|
Local Phone Number |
941-0360
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value per share
|
Trading Symbol |
AEMD
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aethlon Medical (NASDAQ:AEMD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Aethlon Medical (NASDAQ:AEMD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024